Investment Rating - The report maintains a positive outlook on the company, indicating strong growth potential and reaffirming the double-digit revenue growth target for 2026 [5][7]. Core Insights - The company demonstrated robust performance in 2025, with sales increasing by 30% year-on-year to 26.931 billion yuan, exceeding market expectations by 5% [6]. - The net profit for 2025 rose by 40.2% to 8.246 billion yuan, also surpassing market consensus by 11% [6]. - The management highlighted that the performance aligns with the goal of double-digit revenue growth for 2026, with packaging water revenue expected to recover to 2023 levels [7]. Summary by Sections Financial Performance - In 2025, total revenue grew by 22.5% to 52.553 billion yuan, while net profit increased by 30.9% to 15.868 billion yuan [6]. - The growth was driven by strong sales across various product categories, including packaged water (+25%), ready-to-drink tea (+38%), functional beverages (+20%), and juice (+33%) [6]. Market Dynamics - The company is expected to benefit from a recovering packaging water market and the introduction of new products, including electrolyte water [7]. - The PET price has increased by 36% year-on-year, impacting profit margins; however, the company is less sensitive to these fluctuations compared to peers due to its higher profit margins and optimized product mix [8]. Catalysts for Growth - Key growth catalysts include an increasing market share in packaged water, favorable PET price trends, faster-than-expected macroeconomic recovery, continuous new product launches, and strong growth in the no-sugar tea beverage segment [9].

Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 21.18 and a fair value of HKD 29.34 [7]. Core Insights - The company reported a significant increase in net profit, with a year-on-year growth of 220.9% for the year 2025, driven by strong performance in investment services and a tax reversal [8]. - The company declared a dividend of HKD 1.23 per share for 2025, a substantial increase from HKD 0.35 in the previous year, indicating confidence in future business growth and solvency [8]. - The embedded value (EV) increased by 19.8%, with the life insurance EV growing by 18.3%, surpassing industry expectations due to a low base effect from the previous year [8]. Financial Forecasts - The company’s projected embedded value (in million HKD) for 2024A to 2028E is as follows: - 2024A: 234,224 - 2025A: 280,603 - 2026E: 312,386 - 2027E: 350,444 - 2028E: 391,743 - The growth rates for the embedded value are projected at -13.93% for 2024A, followed by 19.80%, 11.33%, 12.18%, and 11.78% for the subsequent years [3]. - The forecasted earnings per share (EPS) for 2026E to 2028E are 7.18, 7.29, and 8.07 HKD, respectively [35]. Business Performance - The company’s net profit for 2025 is expected to reach HKD 27,059 million, reflecting a growth rate of 220.91% compared to the previous year [3]. - The new business value (NBV) is projected to grow by 5.3% year-on-year, with a slight increase in new policies sold [8]. - The company’s net assets are expected to grow by 33.9% year-on-year, primarily due to the doubling of net profit and rising interest rates [8]. Premium Forecast - The new premium forecast for the company from 2023 to 2028 is as follows (in million HKD): - 2023: 186,846 - 2024: 195,303 - 2025: 200,725 - 2026E: 200,747 - 2027E: 207,949 - 2028E: 219,060 - The growth rates for new premiums are expected to be +0.1% for 2026E, +8.8% for 2027E, and +12.1% for 2028E [33].

Investment Rating - The report assigns a "Buy" rating to the company, with a current price of 12.74 HKD and a fair value of 14.64 HKD [8]. Core Insights - The company has shown continuous profit improvement, with a reported revenue of 79.07 billion RMB for 2025, a decrease of 2.0% year-on-year, while the net profit attributable to shareholders increased by 20.5% to 4.50 billion RMB [8]. - The company maintained a 100% dividend payout, reflecting its strong cash flow and commitment to returning value to shareholders [8]. - The second half of 2025 saw a narrowing decline in revenue, with the instant noodle business showing signs of recovery, particularly in high-priced products [8]. - The gross margin improved, with overall gross margin increasing by 1.7 percentage points to 34.8%, driven by cost benefits and product mix optimization [8]. - The report forecasts net profit growth for 2026-2028, with expected figures of 4.54 billion RMB, 4.89 billion RMB, and 5.24 billion RMB respectively, corresponding to a PE ratio of 14, 13, and 12 times [8]. Financial Summary - Revenue projections for 2024 to 2028 are as follows: 80.65 billion RMB (2024), 79.07 billion RMB (2025), 79.91 billion RMB (2026), 81.56 billion RMB (2027), and 83.32 billion RMB (2028) [4]. - The EBITDA is projected to grow from 9.47 billion RMB in 2024 to 11.10 billion RMB in 2028 [4]. - The return on equity (ROE) is expected to increase from 26.2% in 2024 to 35.0% in 2028 [4]. - The report highlights a decrease in employee count by 6.3% to 60,720, indicating ongoing operational efficiency improvements [8].

Investment Rating - The report maintains a "Buy" rating for Swire Properties (01972) [3][8] Core Insights - The report highlights steady growth in mainland retail and continuous dividend increases, with a projected basic profit of HKD 75.4 billion for 2026 and HKD 80.6 billion for 2027, reflecting a year-on-year change of -12.5% and +6.8% respectively [8] - The company reported a total revenue of HKD 16 billion for 2025, representing an 11.2% year-on-year increase, driven by the disposal of non-core properties in the US and Hong Kong [8] - The report emphasizes Swire Properties' competitive advantages, including strategic vision, premium asset locations, and strong management capabilities, positioning it as a leading player in the commercial real estate sector [8] Financial Data and Profit Forecast - Revenue projections for Swire Properties are as follows: - 2024: HKD 14,428 million - 2025: HKD 16,041 million - 2026E: HKD 17,103 million - 2027E: HKD 18,671 million - 2028E: HKD 19,867 million - The expected net profit attributable to ordinary shareholders is projected to be: - 2024: HKD 6,768 million - 2025: HKD 8,620 million - 2026E: HKD 7,544 million - 2027E: HKD 8,055 million - 2028E: HKD 8,064 million [7][9]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company reported a revenue of approximately 20.97 billion RMB for 2025, representing a year-on-year increase of 17.13%. The adjusted net profit was about 2.37 billion RMB, up 51.2% year-on-year, while the net profit attributable to the parent company reached 1.53 billion RMB, a significant increase of 409.7% year-on-year. The company plans to distribute a dividend of 0.11 RMB per share, which corresponds to a cash dividend rate of approximately 50% [1][4] Revenue and Profit Structure - In 2025, the self-operated business revenue reached 20.066 billion RMB, growing by 18% year-on-year, with the flagship brand business transaction scale reaching 2.445 billion RMB, a remarkable increase of 111% year-on-year. The proprietary brand transaction scale within this segment surged to 1.937 billion RMB, up 283% year-on-year. The platform business revenue was 866 million RMB, down 1.7% year-on-year due to a sluggish retail drug market affecting third-party sellers [4][6] - The adjusted net profit margin improved by approximately 0.26 percentage points, reaching 1.13% in 2025, while the net profit margin attributable to the parent company increased by about 0.56 percentage points to 0.73%. The gross profit margin also saw an increase of about 0.87 percentage points, reaching 11% in 2025, primarily driven by the rapid growth of high-margin businesses [4][6] Active User Metrics - The platform's average monthly active buyers reached 461,000, an increase of 6.5% year-on-year, while the average monthly paying buyers grew by 8.5% to 435,000. The business expansion team comprised approximately 2,700 members, with each managing around 200 pharmacies [4][6] Financial Projections - The company is projected to achieve revenues of approximately 23.46 billion RMB, 26.22 billion RMB, and 29.18 billion RMB for 2026, 2027, and 2028, respectively, with year-on-year growth rates of 12%, 12%, and 11%. The net profit attributable to the parent company is expected to be 2.52 billion RMB, 3.62 billion RMB, and 4.76 billion RMB for the same years, reflecting year-on-year growth rates of 64%, 44%, and 32% [6][7]

Investment Rating - The report assigns a "Buy" rating to the company, with a current price of 5.81 HKD and a fair value of 8.48 HKD [3]. Core Insights - The company achieved a full-year revenue of 1.482 billion RMB in 2025, reflecting a year-over-year growth of 10.1%. The net profit for the same period was 339 million RMB, up 23.8% year-over-year. The growth in profit was attributed to increased overseas revenue and improved gross margins from digital orthopedic products and services [7]. - The gross margin for 2025 was reported at 60.5%, an increase of 0.5 percentage points year-over-year, driven by effective cost control and a higher proportion of revenue from overseas and digital orthopedic products [7]. - The orthopedic surgical robot sales saw a remarkable growth rate exceeding 200% [7]. - The company is implementing a "dual-brand" strategy to enhance its presence in overseas markets, with the K3 intelligent surgical robot receiving regulatory approval in May 2025 and the upgraded K3+ model in January 2026. This strategy aims to provide customized prosthetics and orthopedic surgical robots to international clients [7]. Financial Forecast - The projected revenues for 2026, 2027, and 2028 are 1.679 billion RMB, 1.910 billion RMB, and 2.185 billion RMB, respectively, with growth rates of 13.3%, 13.8%, and 14.4% [7]. - The expected net profits for the same years are 419 million RMB, 524 million RMB, and 643 million RMB, with growth rates of 23.7%, 25.0%, and 22.7% [7]. - The report anticipates a PE ratio of 20X for 2026, leading to a fair value estimate of 8.48 HKD per share [7].

Investment Rating - The report maintains a "Buy" rating for China Resources Beer (291.HK) with a target price of HKD 31.0 per share, indicating a potential upside of 22.1% from the current price of HKD 25.38 [1][5][13]. Core Insights - The company's revenue for 2025 is projected at HKD 379.85 billion, reflecting a year-on-year decline of 1.68%, primarily due to the underperformance of its liquor business. The net profit attributable to shareholders is expected to be HKD 33.71 billion, down 28.87% year-on-year, largely impacted by a liquor impairment of HKD 28.77 billion. Excluding this impairment, the adjusted net profit would be HKD 57.24 billion, representing a growth of 19.6% [3][8]. - The beer segment shows resilience, with revenue remaining stable at HKD 382.57 billion and beer sales increasing by 1.4% to 11.03 million tons. The high-end strategy continues to drive growth, with premium and above beer sales rising nearly 10% [3][9]. - The liquor business faced significant challenges, with revenue dropping 30.39% to HKD 14.96 billion. The company has recognized an impairment of HKD 28.77 billion for goodwill related to its liquor business, but the EBITDA for this segment, excluding the impairment, is HKD 2.64 billion [5][12]. Financial Summary - The total share capital is 3.244 billion shares, with a total market capitalization of HKD 823.37 billion and net assets of HKD 359.64 billion. The company’s total assets amount to HKD 686.33 billion [2][3]. - The gross margin improved by 1.4 percentage points to 42.5%, benefiting from product mix optimization and cost savings. Adjusted EBITDA reached HKD 96.11 billion, a year-on-year increase of 17.4% [3][9]. - The report forecasts net profits for 2026-2028 to be HKD 58.95 billion, HKD 63.62 billion, and HKD 68.44 billion, respectively, indicating growth rates of 74.9%, 7.9%, and 7.6% [6][13].

Investment Rating - The report maintains an "Outperform" rating for ANTA Sports [2][20]. Core Insights - Group revenue for 2H25 reached RMB 41.68 billion, representing a year-on-year increase of 12.4%, exceeding expectations. The gross margin for 2H25 was 60.7%, up 0.3 percentage points from 1H25. Operating profit for 2H25 was RMB 7.314 billion, a year-on-year rise of 15.4%, while net profit was RMB 6.664 billion, a year-on-year decrease of 16.9% [4][14]. - The ANTA brand's revenue for 2H25 was RMB 17.80 billion, a year-on-year increase of 2.1%. The brand's operating profit for 2H25 was RMB 3.27 billion, down 7.6% year-on-year, with an operating profit margin of 18.3% [15]. - FILA brand revenue for 2H25 was RMB 14.29 billion, a year-on-year increase of 5.3%, with an operating profit of RMB 3.48 billion, up 15.8% year-on-year, and an operating profit margin of 24.4% [16]. - Other brands achieved revenue of RMB 9.58 billion in 2H25, a year-on-year surge of 57.7%, with an operating profit of RMB 2.28 billion, up 36.0% year-on-year, and an operating profit margin of 23.8% [17]. - The company expects revenue for 2026-2028 to reach RMB 88.02 billion, RMB 96.67 billion, and RMB 105.42 billion respectively, with year-on-year growth of 9.7%, 9.8%, and 9.1% [18]. Financial Projections - The report forecasts net profit attributable to parent shareholders for 2026-2028 to be RMB 14.12 billion, RMB 15.30 billion, and RMB 16.92 billion respectively, with year-on-year growth of 3.9%, 8.3%, and 10.6% [18]. - The expected P/E ratios for 2026-2028 are 13.2x, 12.2x, and 11.0x [18].

Investment Rating - The report maintains an "Outperform the Market" rating for China Jinmao (00817.HK) [5][3] Core Insights - The company achieved a revenue of 59.37 billion yuan in 2025, a year-on-year increase of 1%, and a net profit attributable to shareholders of 1.25 billion yuan, up 18% year-on-year [1][8] - The company recorded a signed sales amount of 113.5 billion yuan in 2025, representing a 16% year-on-year growth, making it the only company among the top 10 real estate firms to achieve sales growth [2][10] - The company has actively replenished its land reserves in core cities, acquiring 21 plots of land with a total value exceeding 100 billion yuan, while also revitalizing 15 existing land projects [2][11] Financial Performance - The gross profit margin for 2025 was 15.5%, an increase of 1 percentage point year-on-year, indicating a recovery in profitability [1][8] - The company successfully reduced its financing costs, with total interest expenses decreasing by 7% year-on-year and financing costs down by 10% [2][11] - As of the end of 2025, the company's net debt to adjusted capital ratio stood at 69%, remaining stable [2][11] Earnings Forecast - The report forecasts revenues and net profits for 2026 and 2027 to be 56.34 billion yuan and 54.54 billion yuan, and 1.1 billion yuan and 1.12 billion yuan respectively, with corresponding EPS of 0.08 yuan for both years [3][16]

Investment Rating - The report assigns a "Buy" rating to China Nonferrous Mining Corporation, with a target price of 14.23 HKD based on a 14x PE for 2026 [3]. Core Insights - The company is expected to double its self-owned copper production during the 15th Five-Year Plan, with significant projects planned in Zambia, the Democratic Republic of the Congo, and Kazakhstan [2][4]. - The company anticipates a net profit of 505 million USD in 2026, with a projected growth in net profit of 25% in 2026 and 26% in 2027 [3][5]. - The report highlights the expected copper price range of 9,500 to 11,000 USD per ton in the short term, driven by supply-demand dynamics and cost factors [4]. Financial Performance and Projections - Revenue for 2025 is projected at 3.42 billion USD, with a decline of 10.4% year-on-year, while net profit is expected to increase by 1.5% to 404 million USD [4][5]. - The company plans capital expenditures of approximately 2.5 billion USD during the 15th Five-Year Plan, with 510 million USD earmarked for 2026 [4]. - The expected earnings per share (EPS) for 2026 is 0.13 USD, with a P/E ratio of 11.23 [5].